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Abstract Adalimumab is a frequently prescribed TNFα
inhibitor for treatment of rheumatoid arthritis. We report on
a patient who probably developed a Miller–Fisher syn-
drome after the second injection of adalimumab.
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Introduction
Rheumatoid arthritis (RA) is a common chronic arthropathy
affecting ≈1% of the adult population worldwide. Tumor
necrosis factor alpha (TNFα) inhibitors have been increas-
ingly used as DMARD therapy in conjunction with
conventional drugs, in particular methotrexate. Adalimumab
is a widely prescribed TNFα inhibitor. We report on a female
patient with RA who developed Miller–Fisher syndrome [1]
after the second injection of adalimumab.
Case presentation
The patient, a 77-year-old female with seropositive erosive
RA, had previously received hydroxychloroquine, gold
salts, penicillamine, sulfasalazine, and cyclosporine without
success. Methotrexate had to be discontinued because of
drug-induced pneumonitis. As a result, she was maintained
on azathioprine (75 mg/day=1 mg/kg) and prednisone (5 mg/
day). In 2006, she underwent a cervical laminectomy C4–C5
and C6–C7with plate from C4 to C6 because of a myelopathy
secondary to cervical osteoarthritis. At surgery, there was no
local rheumatoid pannus. Her medical history included type II
diabetes mellitus, hypertension, hyperlipidemia and ischemic
heart disease.
In 2007, she was started on adalimumab after a RA flare.
Twenty-four hours after the second injection of 40 mg of
adalimumab, she reported dizziness and loss of cutaneous
sensation that progressed proximally in the lower limbs and
she was hospitalized. On admission, the general examina-
tion was unremarkable except for mild fever. The neuro-
logical examination showed ataxia of all four limbs and
disappearance of the deep tendon reflexes in the lower
limbs. The next day, there was a complete loss of
proprioception, loss of balance and impossibility to walk.
One week later, she developed a horizontal nystagmus with
impossibility to lift the upper eyelids [1, 2].
Laboratory tests showed a raised ESR (40 mm in the first
hour) and CRP (69 mg/l). Autoantibodies including anti-
ganglioside antibodies (GQ1b) were negative. The search
for an infection was negative.
Radiological investigations included a cerebral and a
thoraco-abdo-pelvic computed tomography, and a cervical
to lumbar spine MRI; they were all normal. The electro-
myogram showed a decreased evocated sensitive response
to peripheral nerve stimulation on the upper limbs and
absence of this response on the lower limbs. The motor
recording was normal. There was no muscle involvement.
A diagnosis of a Miller–Fisher syndrome [1, 2] was made.
Treatment consisted of high-dose steroids (75 mg/day=
1 mg/kg), gabapentine, and an increased dose of azathio-
prine (75 mg tad). Physical therapy was initiated. The
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biological signs of inflammation disappeared quickly but
the clinical evolution was marked by a slow improvement
over one year of balance, proprioception, and reflexes.
Discussion
The Miller–Fisher syndrome [1, 2] is an autoimmune
polyneuropathy characterized by an ascending muscle
weakness of the limbs, as in the Guillain–Barré syndrome,
with loss of sensation, areflexia, ataxia, and opthalmople-
gia. Although neurological symptoms have been reported
with adalimumab [3], this case reports, to our knowledge,
on the first Miller–Fisher syndrome induced by treatment
with adalimumab. Immunological mechanisms have been
incriminated in the development of this syndrome, though
in our case, anti-ganglioside antibodies were absent. The
lumbar puncture showed an isolated increased protein
content (1,000 mg/l) but the patient underwent a cervical
surgery a few weeks before.
Neurological complications have been described with
several TNFα inhibitors. The use of lenercept in multiple
sclerosis produced worsening of the disease causing the
premature interruption of the study [4]. Similarly, 17 patients
treated with etanercept [3] and two patients treated with
infliximab [3] developed neurological symptoms. These
latter included confusion, ataxia, dysesthesia, paresthesia,
facial paralysis, optical neuritis, hemiparesia, transverse
myelitis and an ascending neuropathy resembling the
Guillain–Barré syndrome. All these cases were proven by a
retrial of the drug. The risk was estimated for etanercept (31
cases for 100,000 patients) and infliximab (41 cases for
100,000) [3]. No case has been described with adalimumab
until now. Therefore, a Miller–Fisher syndrome secondary to
the use of a TNFα inhibitor seems to be a class effect, which
can be, as in our case, rapidly and severely progressive.
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